PT96016A - Processo para a preparacao de uma composicao farmaceutica para a aplicacao subcutanea ou intramuscular contendo polipeptidos - Google Patents

Processo para a preparacao de uma composicao farmaceutica para a aplicacao subcutanea ou intramuscular contendo polipeptidos

Info

Publication number
PT96016A
PT96016A PT96016A PT9601690A PT96016A PT 96016 A PT96016 A PT 96016A PT 96016 A PT96016 A PT 96016A PT 9601690 A PT9601690 A PT 9601690A PT 96016 A PT96016 A PT 96016A
Authority
PT
Portugal
Prior art keywords
subcutaneous
preparation
pharmaceutical composition
containing polypeptides
application containing
Prior art date
Application number
PT96016A
Other languages
English (en)
Other versions
PT96016B (pt
Inventor
Eric-Paul Paques
Original Assignee
Behringwerke Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=6394356&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PT96016(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Behringwerke Ag filed Critical Behringwerke Ag
Publication of PT96016A publication Critical patent/PT96016A/pt
Publication of PT96016B publication Critical patent/PT96016B/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1816—Erythropoietin [EPO]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36—Blood coagulation or fibrinolysis factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/49—Urokinase; Tissue plasminogen activator
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A61K38/57—Protease inhibitors from animals; from humans
    • A61K38/58—Protease inhibitors from animals; from humans from leeches, e.g. hirudin, eglin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Dermatology (AREA)
  • Hematology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
PT96016A 1989-11-29 1990-11-28 Processo para a preparacao de uma composicao farmaceutica para a aplicacao subcutanea ou intramuscular contendo polipeptidos PT96016B (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE3939346A DE3939346A1 (de) 1989-11-29 1989-11-29 Arzneimitel zur subkutanen oder intramuskulaeren applikation enthaltend polypeptide

Publications (2)

Publication Number Publication Date
PT96016A true PT96016A (pt) 1991-09-13
PT96016B PT96016B (pt) 1998-06-30

Family

ID=6394356

Family Applications (1)

Application Number Title Priority Date Filing Date
PT96016A PT96016B (pt) 1989-11-29 1990-11-28 Processo para a preparacao de uma composicao farmaceutica para a aplicacao subcutanea ou intramuscular contendo polipeptidos

Country Status (12)

Country Link
US (1) US5691312A (pt)
EP (1) EP0430200B1 (pt)
JP (1) JP3143470B2 (pt)
KR (1) KR910009246A (pt)
AT (1) ATE106746T1 (pt)
AU (1) AU657466B2 (pt)
CA (1) CA2030988C (pt)
DE (2) DE3939346A1 (pt)
DK (1) DK0430200T3 (pt)
ES (1) ES2057339T3 (pt)
IE (1) IE64080B1 (pt)
PT (1) PT96016B (pt)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5364839A (en) * 1990-06-18 1994-11-15 Genetics Institute, Inc. Osteoinductive pharmaceutical formulations
DE4126984A1 (de) * 1991-08-15 1993-02-18 Boehringer Mannheim Gmbh Verfahren zur herstellung von humanprotein-enthaltenden, gut vertraeglichen arzneimitteln fuer infusions- oder injektionszwecke
SE9300105D0 (sv) * 1993-01-15 1993-01-15 Kabi Pharmacia Ab Stable protein solution
WO1995033474A1 (en) * 1994-06-03 1995-12-14 Tsumura & Co. Medicinal composition
US5770700A (en) * 1996-01-25 1998-06-23 Genetics Institute, Inc. Liquid factor IX formulations
TW518219B (en) 1996-04-26 2003-01-21 Chugai Pharmaceutical Co Ltd Erythropoietin solution preparation
DE69729880T3 (de) * 1996-12-24 2012-05-10 Biogen Idec Ma Inc. Stabile flüssige interferon-zubereitungen
US20030190307A1 (en) 1996-12-24 2003-10-09 Biogen, Inc. Stable liquid interferon formulations
DE10149030A1 (de) 2001-10-05 2003-04-10 Viscum Ag Stabile galenische gefriergetrocknete Arzneimittelzubereitung von rViscumin
JP2005530683A (ja) 2001-12-21 2005-10-13 ノボ ノルディスク ヘルス ケア アクチェンゲゼルシャフト 第ｖｉｉ因子ポリペプチドの液体組成物
CA2476934C (en) 2002-02-27 2009-06-16 Immunex Corporation Stabilized tnfr-fc composition comprising arginine
CN101912601B (zh) 2002-06-21 2012-08-29 诺和诺德医疗保健公司 因子vii多肽的稳定化固体组合物
US7897734B2 (en) 2003-03-26 2011-03-01 Novo Nordisk Healthcare Ag Method for the production of proteins
KR20060015574A (ko) 2003-05-23 2006-02-17 노보 노르디스크 헬스 케어 악티엔게젤샤프트 용액 중 단백질 안정화
EP1656158B1 (en) 2003-08-14 2016-03-09 Novo Nordisk Health Care AG Liquid, aqueous pharmaceutical composition of factor vii polypeptides
EP2311437A1 (en) 2003-12-19 2011-04-20 Novo Nordisk Health Care AG Stabilised compositions of factor VII polypeptides
JP2008543839A (ja) 2005-06-14 2008-12-04 アムジェン インコーポレーテッド 自己緩衝タンパク質製剤
WO2007146945A2 (en) * 2006-06-12 2007-12-21 Aspen Aerogels, Inc. Aerogel-foam composites
WO2009130181A2 (en) * 2008-04-21 2009-10-29 Novo Nordisk Health Care Ag Dry transglutaminase composition
AU2012345777B2 (en) 2011-11-30 2016-05-12 Kindeva Drug Delivery L.P. Microneedle device including a peptide therapeutic agent and an amino acid and methods of making and using the same
ES2939940T3 (es) 2014-03-28 2023-04-28 Univ Duke Tratamiento del cáncer de mama utilizando moduladores selectivos de los receptores de estrógenos
MX384605B (es) 2015-04-29 2025-03-14 Radius Pharmaceuticals Inc Combinación de palbociclib y rad1901 para usarse en el tratamiento de cáncer de mama en un sujeto con cáncer positivo a receptor de estrógeno.
ES3064802T3 (en) 2016-10-21 2026-04-29 Amgen Inc Pharmaceutical formulations and methods of making the same
EP3565542B1 (en) 2017-01-05 2024-04-10 Radius Pharmaceuticals, Inc. Polymorphic forms of rad1901-2hcl
SG11202013177WA (en) 2018-07-04 2021-01-28 Radius Pharmaceuticals Inc Polymorphic forms of rad 1901-2hcl
US12441745B2 (en) 2019-02-12 2025-10-14 Radius Pharmaceuticals, Inc. Processes and compounds

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS56135418A (en) * 1980-03-27 1981-10-22 Green Cross Corp:The Heat treatment of aqueous solution containing 8 factor of coagulation of blood derived from human
GB2079292A (en) 1980-07-05 1982-01-20 Speywood Lab Ltd Blood Clotting Factor Production
US4508709A (en) * 1983-12-05 1985-04-02 Armour Pharmaceutical Company Process for purifying factor VIII:C
EP0156169B1 (en) * 1984-02-29 1991-12-18 Asahi Kasei Kogyo Kabushiki Kaisha An aqueous solution of a tissue plasminogen activator dissolved therein at an increased concentration and a method
US4656034A (en) * 1985-05-20 1987-04-07 Survival Technology, Inc. Absorption enhancing agents
JPS6197229A (ja) * 1984-10-18 1986-05-15 Chugai Pharmaceut Co Ltd 安定なエリトロポエチン製剤
US4839170A (en) * 1985-10-01 1989-06-13 Survival Technology, Inc. Protein absorption enhancing agents
DE3625090A1 (de) * 1986-07-24 1988-01-28 Behringwerke Ag Mittel zur therapie faktor viii-resistenter haemophilie a und verfahren zu seiner herstellung
DE3643182A1 (de) * 1986-12-18 1988-06-30 Behringwerke Ag Arzneimittel enthaltend das gewebeprotein pp4, verfahren zur herstellung von pp4 und zu seiner pasteurisierung sowie die verwendung von pp4
US4857320A (en) 1987-02-19 1989-08-15 Monsanto Company Method of enhancing the solubility of tissue plasminogen activator
DE3729863A1 (de) * 1987-09-05 1989-03-16 Boehringer Mannheim Gmbh Stabilisierte erythropoietin-lyophilisate
DE3718889A1 (de) * 1987-06-05 1988-12-22 Behringwerke Ag Verfahren zur herstellung einer loesung hoher spezifischer volumenaktivitaet von einem protein mit gewebe-plasminogenaktivator (t-pa)-aktivitaet, loesung, enthaltend protein mit t-pa-aktivitaet und verwendung der loesung in der human- und veterinaermedizin
JP2708749B2 (ja) * 1987-08-10 1998-02-04 エーザイ株式会社 修飾型ｔＰＡ含有注射用組成物
DE4126983A1 (de) * 1991-08-15 1993-02-18 Boehringer Mannheim Gmbh Verfahren zur herstellung von humanprotein-enthaltenden, konservierten arzneimitteln fuer infusions- oder injektionszwecke
US5358708A (en) * 1993-01-29 1994-10-25 Schering Corporation Stabilization of protein formulations

Also Published As

Publication number Publication date
CA2030988A1 (en) 1991-05-30
AU6702990A (en) 1991-06-06
CA2030988C (en) 2004-11-16
PT96016B (pt) 1998-06-30
IE904292A1 (en) 1991-06-05
DE59006032D1 (de) 1994-07-14
IE64080B1 (en) 1995-07-12
US5691312A (en) 1997-11-25
DE3939346A1 (de) 1991-06-06
EP0430200B1 (de) 1994-06-08
AU657466B2 (en) 1995-03-16
KR910009246A (ko) 1991-06-28
DK0430200T3 (da) 1994-09-26
ATE106746T1 (de) 1994-06-15
EP0430200A1 (de) 1991-06-05
JPH03170437A (ja) 1991-07-24
JP3143470B2 (ja) 2001-03-07
ES2057339T3 (es) 1994-10-16

Similar Documents

Publication Publication Date Title
DE59006032D1 (de) Arzneimittel zur subkutanen oder intramuskulären Applikation enthaltend Polypeptide.
DE3776946D1 (de) Nasale verabreichung von arzneimitteln.
PT96068A (pt) Processo para a producao de proteina biologicamente activa
BR9710452A (pt) Anïïlogos de exendina processos para sua prepara-Æo e medicamentos contendo os mesmos
PT82834B (pt) Processo para a preparacao de composicoes farmaceuticas, com sulobilizacao de proteinas, usando conjugacao de polimeros
PT93082A (pt) Processo de producao de um derivado de activador de plaminogenio tissular, de plasmideo de expressao e de medicamento contendo o referido derivado
EP0570916A3 (en) Human recombinant serum albumin, process for its preparation and pharmaceutical preparations containing it.
FI893783A0 (fi) Menetelmä diabetes mellituksen hoitoon tarkoitetun farmaseuttisen valmisteen valmistamiseksi
PT693924E (pt) Processos para administracao (in vivo) de substancias biologicas e composicoes utilizadas nestes processos
ATE173478T1 (de) Varianten des pankreatischen rinder- trypsininhibitors, deren herstellung und verwendung
PT97160A (pt) Processo para a preparacao de composicoes estaveis para administracao parenterica contendo uma proteina, peptideo ou polipeptideo biologicamente activo
DE3772521D1 (de) Insulinzubereitung fuer nicht-parenterale verabreichung.
PT88985A (pt) Processo para a preparacao de composicoes farmaceuticas nasais e ou oftalmicas contendo azelastina
SE8602530L (sv) Nasala farmaceutiska kompositioner
FR2768341B1 (fr) Composition pharmaceutique placebo lyophilisable destinee a imiter un medicament, notamment a base de proteines ou de polypeptides
DK610888D0 (da) Cardiodilatinfragmentet, fremgangsmaade til fremstilling deraf samt dets anvendelse
ATE54824T1 (de) System zur arzneistoffabgabe mit erhoehter bioakzeptanz.
DE69425033D1 (de) Verfahren zur Sterilisierung einer menschliches, rekombinantes Serum-albumin enthaltenden pharmazeutischen Zusammensetzung
NO179436C (no) Fremgangsmåte for fremstilling av farmasöytiske produkter for topisk bruk
SE8800080L (sv) Laekemedelskomposition
IL90356A0 (en) Amphiphilic peptides and pharmaceutical compositions containing them
PT92228A (pt) Processo para a preparacao de uma formulacao oral liquida, contendo diclofenac
DK221288D0 (da) 2beta-,16beta-diamino-androstaner og fremgangsmaade til fremstilling deraf samt farmaceutisk middel indeholdende en saadan forbindelse
PT83688B (pt) Processo de preparacao de uma molecula de adn, de um polipeptido e de composicao farmaceutica contendo-o
AU3577589A (en) Methods and compositions for the treatment of mammalian infections employing medicaments comprising hymenoptera venom, proteinaceous or polypeptide components thereof, or analogues of such proteinaceous or polypeptide components

Legal Events

Date Code Title Description
BB1A Laying open of patent application

Effective date: 19910410

FG3A Patent granted, date of granting

Effective date: 19980303

PD3A Change of proprietorship

Owner name: AVENTIS BEHRING GMBH

Effective date: 20000316

MM4A Annulment/lapse due to non-payment of fees, searched and examined patent

Free format text: MAXIMUM VALIDITY LIMIT REACHED

Effective date: 20130304